{"disease":{"id":"recurrent-cervical-carcinoma","name":"recurrent cervical carcinoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02465060","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":6452,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05290935","title":"Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy: Multi-Center Trial","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":122,"lead_sponsor_name":"Lei Li","has_results":false},{"nct_id":"NCT03170570","title":"the Re-irradiation of Recurrent Cervical Cancer by IMRT","phase":"NA","overall_status":"UNKNOWN","enrollment_count":108,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT06238635","title":"Dostarlimab and Cobolimab in Advanced Cervical Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":66,"lead_sponsor_name":"Meghan Shea","has_results":false},{"nct_id":"NCT05310383","title":"Tislelizumab and Radiotherapy for Recurrent Cervical Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":58,"lead_sponsor_name":"Lei Li","has_results":false},{"nct_id":"NCT01266460","title":"Vaccine Therapy in Treating Patients With Persistent or Recurrent Cervical Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":54,"lead_sponsor_name":"Gynecologic Oncology Group","has_results":true},{"nct_id":"NCT07141186","title":"QL1706 in Patients With Recurrent and Metastatic Cervical Cancer Resistant to Prior PD-1/PD-L1 Antibody Therapy","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":50,"lead_sponsor_name":"Tianjin Medical University Cancer Institute and Hospital","has_results":false},{"nct_id":"NCT03602079","title":"Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"Klus Pharma Inc.","has_results":false},{"nct_id":"NCT06157151","title":"PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":46,"lead_sponsor_name":"Precigen, Inc","has_results":false},{"nct_id":"NCT03816553","title":"SHR-1210 in Combination With Apatinib in Patients With Metastatic, Persistent, or Recurrent Cervical Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":45,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT04664244","title":"Combination of Nimotuzumab and Radiotherapy for Recurrent Uterine Cervical Squamous Carcinoma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":43,"lead_sponsor_name":"Lei Li","has_results":false},{"nct_id":"NCT01693783","title":"Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":42,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03439085","title":"DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":41,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT01281852","title":"Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":37,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04188847","title":"First-line Chemotherapy for Recurrent Cervical Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":37,"lead_sponsor_name":"Lei Li","has_results":false},{"nct_id":"NCT04188860","title":"Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"Lei Li","has_results":false},{"nct_id":"NCT01267253","title":"Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":31,"lead_sponsor_name":"Gynecologic Oncology Group","has_results":true},{"nct_id":"NCT03508570","title":"Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":26,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT02257528","title":"Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":26,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03968406","title":"Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":24,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT00039442","title":"Capecitabine in Treating Patients With Persistent or Recurrent Cervical Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":21,"lead_sponsor_name":"Gynecologic Oncology Group","has_results":false},{"nct_id":"NCT05310331","title":"Donafenib for Recurrent Cervical Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Lei Li","has_results":false},{"nct_id":"NCT05310305","title":"PD-1 Antibody and Radiotherapy for Recurrent Cervical Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Lei Li","has_results":false},{"nct_id":"NCT04635956","title":"Camrelizumab Combined With Chemotherapy for Recurrent or Advanced Cervical Neuroendocrine Carcinomas","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Lei Li","has_results":false},{"nct_id":"NCT03452332","title":"Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04574635","title":"Human Papilloma Virus (HPV) Circulating Tumor DNA (ctDNA) in Cervical Cancer","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":18,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT03277482","title":"Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":16,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT02164461","title":"Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"Advaxis, Inc.","has_results":true},{"nct_id":"NCT02921269","title":"Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":11,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03345784","title":"Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":10,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT06865677","title":"Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true}],"total":31},"guidelines":[],"source":"Drug Landscape verified database"}